SCHEMBL3939869

SCHEMBL3939869

COC(=O)c1cc(NC(=O)c2cc(NC(=O)c3cc(NC(=O)c4cc(NC(=O)OC(C)(C)C)cn4C)cn3C)cn2C)cn1C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RY12 Q9H244 1/20 0.42
TOP1 P11387 2/20 0.39
HRAS P01112 1/20 0.39
ESR1 P03372 1/20 0.39
ESR2 Q92731 1/20 0.39
PRKCA P17252 1/20 0.39
MAPT P10636 2/20 0.38
KDM4E B2RXH2 1/20 0.38
POLB P06746 1/20 0.38
HIF1A Q16665 1/20 0.38
LEF1 Q9UJU2 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
NAMPT P43490 1/20 0.38
HPSE Q9Y251 1/20 0.37
HDAC3 O15379 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC2 Q92769 1/20 0.37
HDAC8 Q9BY41 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
PRKDC P78527 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2028885 1.00 P2RY12 (0.42) P2RY12TOP1HRASESR1ESR2
SCHEMBL3943496 1.00 P2RY12 (0.42) P2RY12TOP1HRASESR1ESR2
SCHEMBL4636432 1.00 P2RY12 (0.42) P2RY12TOP1HRASESR1ESR2
SCHEMBL3929339 1.00 P2RY12 (0.42) P2RY12TOP1HRASESR1ESR2
SCHEMBL2392134 0.95 HDAC3 (0.39) P2RY12KDM4ELEF1HDAC3HDAC1
SCHEMBL13879756 0.92 P2RY12 (0.38) P2RY12TOP1HRASESR1ESR2
SCHEMBL18574370 0.90 CYP17A1 (0.43) P2RY12MAPTLEF1RXFP1NAMPT
SCHEMBL2028706 0.90 CYP17A1 (0.43) P2RY12MAPTLEF1RXFP1NAMPT
SCHEMBL16710923 0.90 CYP17A1 (0.43) P2RY12MAPTLEF1RXFP1NAMPT
SCHEMBL18574436 0.89 RXFP1 (0.50) MAPTKDM4ERXFP1NAMPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210106612-A1 TARGET GENE TRANSCRIPTIONAL REPRESSION INHIBITOR THAT CAN BE DESIGNED IN A SEQUENCE-SPECIFIC MANNER, COMPOSITION CONTAINING SAME, AND USE THEREOF NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITY (JP) 2021-04-15 US disclosed
US-20200289659-A1 CONJUGATES FOR TREATING DISEASES ENDOCYTE INC (US) 2020-09-17 US disclosed
US-10624972-B2 Conjugates for treating diseases ENDOCYTE, INC. (US) 2020-04-21 US disclosed
US-9550787-B2 Benzodiazepine derivatives IMMUNOGEN, INC. (US) 2017-01-24 US disclosed
WO-2016148674-A1 CONJUGATES FOR TREATING DISEASES ENDOCYTE, INC. (US) 2016-09-22 WO disclosed
US-20160222013-A1 NOVEL BENZODIAZEPINE DERIVATIVES IMMUNOGEN, INC. 2016-08-04 US disclosed
US-8637664-B2 Alkyl 4- [4- (5-oxo-2,3,5, 11a-tetrahydo-5H-pyrrolo [2, 1-c] [1,4] benzodiazepine-8-yloxy)-butyrylamino]-1H-pyrrole-2-carboxylate derivatives and related compounds for the treatment of a proliferative disease SPIROGEN SARL (CH) 2014-01-28 US disclosed
US-20130302357-A1 NOVEL BENZODIAZEPINE DERIVATIVES IMMUNOGEN, INC. 2013-11-14 US disclosed
EP-1931671-B1 ALKYL 4- [4- (5-OXO-2, 3, 5, 11A-TETRAHYD0-5H-PYRR0L0 [2, 1-C][1, 4]BENZODIAZEPINE-8-YLOXY) -BUTYRYLAMINO]-1H-PYRROLE-2-CARBOXYLATE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF A PROLIFERATIVE DISEASE SPIROGEN LTD (GB) 2009-04-08 EP disclosed
US-20080214525-A1 Alkyl 4- [4- (5-Oxo-2,3,5, 11A-Tetrahydo-5H-Pyrrolo [2, 1-C] [1,4] Benzodiazepine-8-Yloxy) -Butyrylamino]-1H-Pyrrole-2-Carboxylate Derivatives and Related Compounds For the Treatment of a Proliferative Disease SPIROGEN LIMITED (GB) 2008-09-04 US disclosed
US-20070154906-A1 Methods to identify therapeutic candidates SPIROGEN LTD. (GB) 2007-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160222013-A1 NOVEL BENZODIAZEPINE DERIVATIVES GABRB1, GABRB3, GABRA1 P2RY12 1571/4885TOP1 1241/4885HRAS 4284/4885
US-20210106612-A1 TARGET GENE TRANSCRIPTIONAL REPRESSION INHIBITOR THAT CAN BE DESIGNED IN A SEQUENCE-SPECIFIC MANNER, COMPOSITION CONTAINING SAME, AND USE THEREOF CTCF, DNMT1, TET1 P2RY12 4843/4885TOP1 433/4885HRAS 4459/4885
US-10624972-B2 Conjugates for treating diseases CD79B, MALT1, TPMT P2RY12 3065/4885TOP1 1359/4885HRAS 1340/4885
US-20200289659-A1 CONJUGATES FOR TREATING DISEASES CD79B, MALT1, TPMT P2RY12 3065/4885TOP1 1359/4885HRAS 1340/4885
US-20080214525-A1 Alkyl 4- [4- (5-Oxo-2,3,5, 11A-Tetrahydo-5H-Pyrrolo [2, 1-C] [1,4] Benzodiazepine-8-Yloxy) -Butyrylamino]-1H-Pyrrole-2-Carboxylate Derivatives and Related Compounds For the Treatment of a Proliferative Disease CCNY, NR0B1, CNR1 P2RY12 3903/4885TOP1 713/4885HRAS 908/4885
US-20130302357-A1 NOVEL BENZODIAZEPINE DERIVATIVES GABRB1, GABRB3, GABRA1 P2RY12 1571/4885TOP1 1241/4885HRAS 4284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.